The investment firm acquired 1.72 million shares of GENB in Q1, marking its first position in the post-IPO drug developer.
HarbourVest Partners disclosed a new $21.03 million stake in Generate Biomedicines (NASDAQ:GENB) on May 15, 2026, purchasing 1,722,210 shares in the first quarter. The position was valued at $21.53 million as of March 31, 2026, reflecting share purchases and price movements.
The fund’s post-trade holding represents 21% of its 13F reportable assets under management. Other top holdings include KLAR at $65.76 million and YMM at $7.95 million. GENB shares closed at $13.12 on Friday, down 12.5% from its $16 IPO price in February.
Generate Biomedicines focuses on protein-based therapeutics, utilizing machine learning and computational biology for drug development.